- £4.96bn
- £6.04bn
- $2.14bn
- 89
- 19
- 66
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.82 | ||
| PEG Ratio (f) | 1.55 | ||
| EPS Growth (f) | 13.01% | ||
| Dividend Yield (f) | 2.28% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 25.58 | ||
| Price to Sales | 2.74 | ||
| EV to EBITDA | 14.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.02% | ||
| Return on Equity | 9.34% | ||
| Operating Margin | 13.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,827.2 | 1,894.3 | 2,038.3 | 2,072.5 | 2,142.4 | 2,286.1 | 2,376.8 | 3.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -30.56 | -10.45 | +0.01 | +41.13 | -6.06 | +58.39 | +13.01 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence and Critical Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
Directors
- John Mcadam NEC
- Karim Bitar CEO (56)
- Frank Schulkes CFO (59)
- Supratim Bose CEX
- Mani Gopal CEX
- Kjersti Grimsrud CEX
- John Lindskog CEX
- Seth Segel CEX
- David Shepherda CEX
- Natalia Kozmina CHO
- Adam Deutsch EVP
- Donal Balfe EVP
- Divakar Ramakrishnan CTO
- Clare Bates SEC
- Sten Scheibye NED (70)
- Rick Anderson NID (60)
- Regina Benjamin NID (64)
- Margaret Ewing NID (66)
- Constantin Freng NID
- Heather Mason NID (58)
- Brian May NID
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 6th, 2016
- Public Since
- October 26th, 2016
- No. of Employees
- 10,129
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 2,049,789,559
- Address
- 7th Floor, 20 Eastbourne Terrace, LONDON, W2 6LG
- Web
- https://www.convatecgroup.com/
- Phone
- Auditors
- Deloitte LLP
Latest News for CTEC
Upcoming Events for CTEC
Full Year 2024 ConvaTec Group PLC Earnings Release
ConvaTec Group PLC Annual Shareholders Meeting
Similar to CTEC
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 19:03 UTC, shares in ConvaTec are trading at 241.80p. This share price information is delayed by 15 minutes.
Shares in ConvaTec last closed at 241.80p and the price had moved by -1.55% over the past 365 days. In terms of relative price strength the ConvaTec share price has underperformed the FTSE All Share Index by -13.09% over the past year.
The overall consensus recommendation for ConvaTec is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe ConvaTec dividend yield is 2.13% based on the trailing twelve month period.
Last year, ConvaTec paid a total dividend of $0.06, and it currently has a trailing dividend yield of 2.13%. We do not have any data on when ConvaTec is to next pay dividends.
We do not have data on when ConvaTec is to next pay dividends. The historic dividend yield on ConvaTec shares is currently 2.13%.
To buy shares in ConvaTec you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 241.80p, shares in ConvaTec had a market capitalisation of £4.96bn.
Here are the trading details for ConvaTec:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CTEC
Based on an overall assessment of its quality, value and momentum ConvaTec is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ConvaTec is 300.09p. That is 24.11% above the last closing price of 241.80p.
Analysts covering ConvaTec currently have a consensus Earnings Per Share (EPS) forecast of $0.15 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ConvaTec. Over the past six months, its share price has underperformed the FTSE All Share Index by -5.62%.
As of the last closing price of 241.80p, shares in ConvaTec were trading +0.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ConvaTec PE ratio based on its reported earnings over the past 12 months is 17.82. The shares last closed at 241.80p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ConvaTec's management team is headed by:
- John Mcadam - NEC
- Karim Bitar - CEO
- Frank Schulkes - CFO
- Supratim Bose - CEX
- Mani Gopal - CEX
- Kjersti Grimsrud - CEX
- John Lindskog - CEX
- Seth Segel - CEX
- David Shepherda - CEX
- Natalia Kozmina - CHO
- Adam Deutsch - EVP
- Donal Balfe - EVP
- Divakar Ramakrishnan - CTO
- Clare Bates - SEC
- Sten Scheibye - NED
- Rick Anderson - NID
- Regina Benjamin - NID
- Margaret Ewing - NID
- Constantin Freng - NID
- Heather Mason - NID
- Brian May - NID